Tg(tetO-DBT)A1Geh
Transgene Detail
|
Symbol: |
Tg(tetO-DBT)A1Geh |
Name: |
transgene insertion A1, Gregg E Homanics |
MGI ID: |
MGI:3704903 |
Synonyms: |
TRE-E2 (line A) |
Transgene: |
Tg(tetO-DBT)A1Geh Location: unknown
|
Alliance: |
Tg(tetO-DBT)A1Geh page
|
|
|
Transgene Type: |
|
Transgenic (Epitope tag, Humanized sequence, Hypomorph, Inducible, Inserted expressed sequence) |
Inducer: |
|
doxycycline/tetracycline |
Mutation: |
|
Insertion
|
|
|
Tg(tetO-DBT)A1Geh expresses
1 gene
Transgene expresses:
Organism |
Expressed Gene |
Homolog in Mouse |
Note |
human |
DBT (1629) |
|
|
|
|
|
Mutation details: The TRE-E2 (or tetO-DBT) transgene contains a tetracycline response element and minimal human CMV promoter controlling a human E2 subunit (DBT gene) cDNA which has been modified to contain a 4x alanine linker followed by a c-myc epitope tag at the carboxy terminus to facilitate detection. Levels of the human E2 protein are approximately equal to mouse E2 protein in livers of control mice. However, when crossed to animals that express a transgene encoding the tetracycline-regulated transactivator protein (Tg(tTALap)5Bjd) and are homozygous for a knockout allele of mouse E2 (Dbttm1Geh) are treated with doxycycline, the E2 protein levels correlate with only ~5-6% of normal branched-chain keto acid dehydrogenase (BCKDH) activity. It is one hypothesis that the addition of the c-myc tag interferes with BCKDH subunit assembly (ie. interaction of the human E2 subunit with mouse E1 and E3 complexes), thus reducing enzymatic activity.
(J:119973)
|
|
|
View phenotypes and curated references for all genotypes (concatenated display).
|
|
Mouse strains and cell lines
available from the International Mouse Strain Resource
(IMSR) |
Carrying this Mutation: |
Mouse Strains: 1 strain available
Cell Lines: 0 lines available
|
|
Original: |
J:119973 Homanics GE, et al., Production and characterization of murine models of classic and intermediate maple syrup urine disease. BMC Med Genet. 2006;7:33 |
All: |
3 reference(s) |
|